BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Carboplatin: trial readouts and FDA decisions
26 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 31 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, Akeso, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Innovent Biologics (Suzhou) Co. Ltd., CSPC Megalith Biopharmaceutical Co., Ltd., Nanjing Leads Biolabs Co., Ltd, Shanghai Hengrui Pharmaceutical Co., Ltd., Tesaro, Inc., CSPC Megalith Biopharmaceutical Co., Ltd., Lantern Pharma Inc., Mabscale, LLC, Eikon Therapeutics, Qilu Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Boehringer Ingelheim, GlaxoSmithKline, Shanghai JMT-Bio Inc., Nanjing Leads Biolabs Co., Ltd, CanariaBio Inc., RemeGen Co., Ltd., CStone Pharmaceuticals, Seagen, a wholly owned subsidiary of Pfizer, Gilead Sciences, Bristol-Myers Squibb, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd, AbbVie, Shanghai Hengrui Pharmaceutical Co., Ltd., Takeda, Arcus Biosciences, Inc., Bio-Thera Solutions, mAbxience Research S.L., Klus Pharma Inc., Regeneron Pharmaceuticals, CrystalGenomics, Inc., Hoffmann-La Roche, Actuate Therapeutics Inc., Tesaro, Inc., CSPC Megalith Biopharmaceutical Co., Ltd., Mabscale, LLC, Qilu Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Nanjing Leads Biolabs Co., Ltd, RemeGen Co., Ltd., Seagen, a wholly owned subsidiary of Pfizer, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd, Shanghai Hengrui Pharmaceutical Co., Ltd., Arcus Biosciences, Inc., CrystalGenomics, Inc., TJ Biopharma Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Tesaro, Inc., CSPC Megalith Biopharmaceutical Co.,Ltd., Mabscale, LLC, Qilu Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Nanjing Leads Biolabs Co.,Ltd, RemeGen Co., Ltd., Seagen, a wholly owned subsidiary of Pfizer, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Genelux Corporation, Shanghai Runshi Pharmaceutical Technology Co., Ltd, Shanghai Hengrui Pharmaceutical Co., Ltd., Arcus Biosciences, Inc., CrystalGenomics, Inc., TJ Biopharma Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer | Endometrial Neoplasms | active not recruiting | 990 |
| 2026-11-26 est. | P3 | Tesaro, Inc. | NCT03981796 A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endome | Neoplasms | active not recruiting | 785 |
| 2026-11-30 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | recruiting | 170 |
| 2026-11-30 est. | P2 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No | Non-Small Cell Lung Cancer | not yet recruiting | 120 |
| 2026-12 est. | P2 | Lantern Pharma Inc. LTRN | NCT05456256 A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung | recruiting | 90 |
| 2026-12 est. | P3 | Mabscale, LLC | NCT05654454 A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | recruiting | 620 |
| 2026-12 est. | P2 | Eikon Therapeutics EIKN | NCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | NSCLC | active not recruiting | 70 |
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06754644 A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC | NSCLC | recruiting | 808 |
| 2026-12 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | Ovarian Cancer | recruiting | 150 |
| 2026-12 est. | P1/P2 | Akeso | NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal | recruiting | 230 |
| 2026-12-10 est. | P3 | Boehringer Ingelheim | NCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standar | Lung Cancer, Non-squamous, Non-small Cell | active not recruiting | 428 |
| 2026-12-14 est. | P2 | GlaxoSmithKline | NCT06317311 A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | Carcinoma | active not recruiting | 41 |
| 2026-12-16 est. | P3 | Shanghai JMT-Bio Inc. | NCT06747338 A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | Early or Locally Advanced HER2-positive Breast Cancer | active not recruiting | 520 |
| 2026-12-24 est. | P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Advanced Solid Tumour | recruiting | 250 |
| 2026-12-26 est. | P3 | CanariaBio Inc. | NCT04498117 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Fal | active not recruiting | 615 |
| 2026-12-28 est. | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | Advanced Neuroendocrine Carcinoma | recruiting | 178 |
| 2026-12-31 est. | P1/P2 | Akeso | NCT05229497 A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | Advanced Malignant Tumors | active not recruiting | 154 |
| 2026-12-31 est. | P3 | RemeGen Co., Ltd. | NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | Urothelial Carcinoma; HER2-expressing | recruiting | 452 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-01-11 est. | P3 | AstraZeneca AZN | NCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EG | Metastatic Non-small Cell Lung Cancer | active not recruiting | 768 |
| 2027-01-29 est. | P3 | Seagen, a wholly owned subsidiary of Pfizer | NCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Urothelial Carcinoma | active not recruiting | 412 |
| 2027-02 est. | P3 | Gilead Sciences GILD | NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Ad | Triple Negative Breast Cancer; PD-L1 Positive | active not recruiting | 443 |
| 2027-02-05 est. | P2 | Bristol-Myers Squibb BMY | NCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Un | Non-Small Cell Lung Cancer | active not recruiting | 76 |
| 2026-12 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients Wi | Non-Small Cell Lung Cancer | active not recruiting | 432 |
| 2026-12 est. | P3 | Genelux Corporation GNLX | NCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primar | recruiting | 186 |
| 2027-02 est. | P2 | Genelux Corporation GNLX | NCT06463665 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; M | recruiting | 142 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. | Unresectable Locally Advanced or Metastatic Solid Tumors | not yet recruiting | 380 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Canc | High Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer | active not recruiting | 125 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherap | Carcinoma, Non-Small-Cell Lung | active not recruiting | 103 |
| 2026-10 est. | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT07229729 A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | recruiting | 300 |
| 2026-10 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 100 |
| 2026-10 est. | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06512051 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | 248 |
| 2026-09-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 506 |
| 2026-09-22 | P3 | Takeda TAK | NCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | 354 |
| 2026-09-17 | P2 | Arcus Biosciences, Inc. RCUS | NCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Can | completed | 169 |
| 2026-09 est. | P2/P3 | Bio-Thera Solutions | NCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | Cervical Cancer | recruiting | 526 |
| 2026-08-31 est. | P3 | mAbxience Research S.L. | NCT06687369 A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer | active not recruiting | 726 |
| 2026-08-31 | P2 | Klus Pharma Inc. | NCT05816252 A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | Non-small Cell Lung Cancer | active not recruiting | 356 |
| 2026-08-24 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in A | Resectable Non-small Cell Lung Cancer | active not recruiting | 195 |
| 2026-08-17 | P3 | AstraZeneca AZN | NCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | Metastatic Non-small Cell Lung Cancer | active not recruiting | 895 |
| 2026-08 est. | P2 | CrystalGenomics, Inc. | NCT05841472 Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non- | Non Squamous Non Small Cell Lung Cancer | recruiting | 60 |
| 2026-08 est. | P2 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | Non-small Cell Lung Cancer | recruiting | 110 |
| 2026-07-31 | P3 | Hoffmann-La Roche | NCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | completed | 11 |
| 2026-07-30 est. | P3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01) | EGFR-mutated Locally Advanced or Metastatic NSCLC | recruiting | 380 |
| 2026-07-10 | P3 | AstraZeneca AZN | NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tu | Non-small Cell Lung Cancer | active not recruiting | 25 |
| 2026-07-06 | P3 | AstraZeneca AZN | NCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treat | Carcinoma; Non-Small-Cell Lung | active not recruiting | 341 |
| 2026-07 est. | P2 | Akeso | NCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | NSCLC | active not recruiting | 265 |
| 2026-06-30 est. | P1/P2 | Akeso | NCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | Advanced Non-small-cell Lung Cancer | active not recruiting | 233 |
| 2026-06-15 est. | P2/P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06211023 A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | Ovarian Cancer | unknown | 520 |
| 2026-06-15 | P3 | Merck Sharp & Dohme LLC MRK | NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemora | Carcinoma, Non-Small-Cell Lung | completed | 610 |
| 2026-06-09 | P3 | AstraZeneca AZN | NCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small C | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | 454 |
| 2026-06-01 | P3 | AstraZeneca AZN | NCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable | Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer | active not recruiting | 1246 |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
| 2026-08-30 est. | P2 | TJ Biopharma Co., Ltd. | NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Loca | Non Small Cell Lung Cancer | active not recruiting | 150 |
| 2026-08 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06382116 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) | Non-small Cell Lung Cancer | active not recruiting | 432 |
| 2026-07-07 | P2 | AstraZeneca AZN | NCT06194448 To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations | Lung Cancer | active not recruiting | 76 |
| 2026-05-31 | P2 | Akeso | NCT05932212 AK104 for Recurrent or Metastatic Vulvar Cancer | Vulvar Cancer | terminated | 20 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.